Your search found 4 Results
AIDS WEEKLY PLUS. 1999 Jul 12-19; 7.AIDS-related mortality has declined significantly since the mid-1990s, although the rate of new infections has remained steady. While recent data indicate that fewer teenagers are having sex and more are using condoms, 20% of AIDS cases in Massachusetts are young adults who were probably infected as teens. There is now a rebirth of denial and considerable complacency about the reality of the HIV/AIDS pandemic. Part of that complacency stems from the development and use of protease inhibitors since 1996, a class of drugs capable of extending the lives of people infected with HIV. The initial success rates of these drugs have led many people to believe that AIDS is no longer life-threatening, but rather manageable over the long term. However, these drugs are complex and there is much misinformation about their success rates. The effectiveness of protease inhibitors has been short-lived in many patients, and sometimes ineffective in people who could not adhere to the strict drug regimen. Thousands of people participated in AIDS Action Committee's 14th annual AIDS Walk to raise awareness and pay tribute to those who have been affected by the disease.
BMJ. British Medical Journal. 1999 Mar 20; 318(7186):757.Against a background of scams to treat HIV/AIDS, the government's erratic approach to the epidemic, and an increasingly cynical but desperate public, a team from the Medical University of South Africa recently announced Inactivan as an anabolic steroid which stops HIV from replicating in white blood cells. The development of the drug was announced in a well-publicized press conference after a 5-day trial on humans. However, few people in South Africa are ready to accept the team's findings since it comes shortly after 2 poorly-qualified scientists claimed to have found a cure for AIDS in 1998. Their drug, Virodene, was actually a toxic industrial solvent. South Africa's minister of health, Dr. Nkosazana Dlamini-Zuma, tarnished her reputation by associating herself with the drug, which had not been through any of the usual research protocols, peer review, or drug regulatory mechanisms.
Perceptions and realities: How safe is the pill? The role of the media, healthcare providers, and the pharmaceutical industry in shaping American women's perceptions about birth control. Q and A.
New York, New York, AGI, 1996 Jan 31. 4 p. (Emerging Issues in Reproductive Health: A Briefing Series for Journalists)Contraceptive choice and usage is affected by various factors at different stages of reproductive life including childbearing hopes, sexual behavior, health history, exposure to sexually transmitted diseases (STDs), ability to use a method consistently and correctly, the side effects and/or health benefits of various methods, and the degree of risk associated with unplanned pregnancy. Survey data indicate that most adults in the US gain family planning information from health professionals as well as from friends and family and the mass media. Perceptions about various methods can influence contraceptive usage in general and method choice in particular. While a majority of US adults find oral contraceptives (OCs) "very" or "somewhat" safe, 21% think OCs are somewhat unsafe, and 11% find them very unsafe. Most safety concerns center on the inability of the OC to protect from STDs and ignore specific health effects that vary for individual women. The fact is that failure to use a contraceptive poses greater risk than any method and that OCs are effective contraceptives that do not hinder future fertility. While the relationship of OC use and breast cancer remains uncertain, OCs are known to protect against ovarian and endometrial cancers. OC use is associated with a relatively small increased risk of cardiovascular disease, and the risk increases in older women and women who smoke. Pregnancy also increases the risk of cardiovascular disease. Recent studies reporting 1) an increased risk of venous thrombosis and 2) a decreased risk of myocardial infarction with new formulations of the OC underscore the importance of taking individual circumstances into account when prescribing OCs. The new studies also indicate a need for additional research on the effects of OC use.
Lancet. 1996 Jun 15; 347(9016):1688.Professor Arthur Obel, a Kenyan scientist who claims to have found the cure for acquired immunodeficiency syndrome (AIDS), through treatment with either of two drugs (Kemron and Pearl Omega) is being sued by patients upon whom Kemron was tested, and Pearl Omega has been banned by the Kenyan Ministry of Health. The backlog of cases in the Kenyan judicial system will allow Obel to avoid answering questions about Kemron, which was launched as an AIDS cure in 1993, while the case is coming to court. Obel then announced in a book, which was published in March, that Pearl Omega had converted the positive serostatus for human immunodeficiency virus (HIV) of seven patients. The Kenyan government had initially supported further clinical trials of Pearl Omega, which was announced to parliament by Assistant Health Minister Basil Criticos on April 24. A week later, Health Minister Joshua Angatia denounced Pearl Omega as an herbal concoction and stated that Obel had "bent the rules." Philip Mbithi, an old schoolfriend of Obel and former Chief Secretary in the Office of the President, is thought to have secured extensive research funds for Obel, who had compared himself to historical figures who had made important discoveries that were initially greeted with skepticism. Obel's reputation with the public is far from discredited. He was cheered during a lecture at Kenyatta University in Nairobi when he offered to donate Pearl Omega to the campus; in the same talk, he said that condoms imported from Europe were infected with HIV, a statement the government has yet to condemn.